发病机制
血管收缩
缺氧性肺血管收缩
肺动脉高压
医学
氧化应激
炎症
病理生理学
血管生成
胚胎血管重塑
内科学
内皮功能障碍
心脏病学
病理
免疫学
癌症研究
作者
Colin E. Evans,Nicholas D Cober,Zhiyu Dai,Duncan J. Stewart,You‐Yang Zhao
出处
期刊:The European respiratory journal
[European Respiratory Society]
日期:2021-01-28
卷期号:58 (3): 2003957-2003957
被引量:188
标识
DOI:10.1183/13993003.03957-2020
摘要
Pulmonary arterial hypertension (PAH) is a devastating disease that involves pulmonary vasoconstriction, small vessel obliteration, large vessel thickening and obstruction, and development of plexiform lesions. PAH vasculopathy leads to progressive increases in pulmonary vascular resistance, right heart failure and, ultimately, premature death. Besides other cell types that are known to be involved in PAH pathogenesis ( e.g. smooth muscle cells, fibroblasts and leukocytes), recent studies have demonstrated that endothelial cells (ECs) have a crucial role in the initiation and progression of PAH. The EC-specific role in PAH is multi-faceted and affects numerous pathophysiological processes, including vasoconstriction, inflammation, coagulation, metabolism and oxidative/nitrative stress, as well as cell viability, growth and differentiation. In this review, we describe how EC dysfunction and cell signalling regulate the pathogenesis of PAH. We also highlight areas of research that warrant attention in future studies, and discuss potential molecular signalling pathways in ECs that could be targeted therapeutically in the prevention and treatment of PAH.
科研通智能强力驱动
Strongly Powered by AbleSci AI